Sera from patients with multifocal motor neuropathy disrupt the blood-nerve barrier

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 5, 2014, Pages 526-537

  Shimizu, Fumitaka ^a   Omoto, Masatoshi ^a   Sano, Yasuteru ^a   Mastui, Naoko ^b   Miyashiro, Ai ^b   Tasaki, Ayako ^a   Maeda, Toshihiko ^a   Koga, Michiaki ^a   Kaji, Ryuji ^b   Kanda, Takashi ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 5; FLUORESCEIN SODIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; TIGHT JUNCTION PROTEIN; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADOLESCENT; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOCRINE EFFECT; BLOOD NERVE BARRIER; CELL DISRUPTION; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRIC RESISTANCE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; INTRACELLULAR SIGNALING; MALE; MICROVASCULAR ENDOTHELIAL CELL; MIDDLE AGED; MOLECULAR PATHOLOGY; MOTOR NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SERUM CHARACTERISTICS; TRANSENDOTHELIAL ELECTRICAL RESISTANCE; UPREGULATION; YOUNG ADULT;

BLOOD-BRAIN BARRIER; IMMUNOLOGY; NEUROCHEMISTRY; NEUROMUSCULAR; NEUROPATHY;

ADOLESCENT; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD-NERVE BARRIER; CASE-CONTROL STUDIES; CELL CULTURE TECHNIQUES; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYNEUROPATHIES; SERUM; TIGHT JUNCTIONS; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 84898925618     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305405     Document Type: Article

References (40)

1. Parry GJ, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988;11:103-7. (Pubitemid 18039607)
2. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001;115:4-18. (Pubitemid 32245648)
3. Muley SA, Parry GJ. Multifocal motor neuropathy. J Clin Neurosci 2012;19:1201-9.
4. Meuth SG, Kleinschnitz C. Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options. Eur Neurol 2010;63:193-204.
5. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005;31:663-80. (Pubitemid 40734675)
6. Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 2011;8:48-58.
7. van der Pol WL, Cats EA, van den Berg LH. Intravenous immunoglobulin treatment in multifocal motor neuropathy. J Clin Immunol 2010;30:S79-83.
8. Umapathi T, Hughes RA, Nobile-Orazio E, et al. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 2012;(4):CD003217.
9. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, et al. Multifocal motor neuropathy. Lancet Neurol 2005;4:309-19. (Pubitemid 40545042)
10. Yuki N, Watanabe H, Nakajima T, et al. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011;82:87-91.
11. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27:3956-67. (Pubitemid 46597169)
12. Willison HJ, Halstead SK, Beveridge E, et al. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome. J Neuroimmunol 2008;15:172-82.
13. Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci USA 1994;91:5705-9. (Pubitemid 24174397)
14. Abe M, Sano Y, Maeda T, et al. Establishment and characterization of human peripheral nerve microvascular endothelial cell lines: a new in vitro blood-nerve barrier (BNB) model. Cell Struct Funct 2012;37:89-100.
15. Kanda T, Numata Y, Mizusawa H. Chronic inflammatory demyelinating polyneuropathy: decreased claudin-5 and relocated ZO-1. J Neurol Neurosurg Psychiatry 2004;75:765-9. (Pubitemid 38526691)
16. Kaji R, Hirota N, Oka N, et al. Anti-GM1 antibodies and impaired blood-nerve barrier may interfere with remyelination in multifocal motor neuropathy. Muscle Nerve 1994;17:108-10.
17. Oh SJ, Claussen GC, Odabasi Z, et al. Multifocal demyelinating motor neuropathy: pathologic evidence of 'inflammatory demyelinating polyradiculoneuropathy'. Neurology 1995;45:1828-32. (Pubitemid 27122952)
18. Taylor BV, Dyck PJ, Engelstad J, et al. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol 2004;63:129-37. (Pubitemid 38174778)
19. van Schaik IN, Léger JM, Nobile-Orazio E, et al. Joint Task Force of the EFNS and the PNS.Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 2010;15:295-301.
20. Brooks BR, Miller RG, Swash M, et al.; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-9.
21. Shimizu F, Sano Y, Abe MA, et al. Peripheral nerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors. J Cell Physiol 2011;226:255-66.
22. Corse AM, Chaudhry V, Crawford TO, et al. Sensory nerve pathology in multifocal motor neuropathy. Ann Neurol 1996;39:319-25. (Pubitemid 26100755)
23. Bouche P, Moulonguet A, Younes-Chennoufi AB, et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995;59:38-44.
24. Santoro M, Uncini A, Corbo M, et al. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol 1992;31:385-90.
25. Arasaki K, Kusunoki S, Kudo N, et al. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve 1993;16:587-93. (Pubitemid 23157329)
26. Takigawa T, Yasuda H, Kikkawa R, et al. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol 1995;37:436-42.
27. Roberts M, Willison HJ, Vincent A, et al. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol 1995;38:111-18.
28. Saito K, Shimizu F, Koga M, et al. Blood-brain barrier destruction determines Fisher/ Bickerstaff clinical phenotypes: an in vitro study. J Neurol Neurosurg Psychiatry 2013;84:756-65.
29. Brannagan TH III, Alaedini A, Gladstone DE. High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy. Muscle Nerve 2006;34:246-50. (Pubitemid 44167810)
30. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-8.
31. Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-42. (Pubitemid 23081153)
32. Kanda T, Iwasaki T, Yamawaki M, et al. Isolation and culture of bovine endothelial cells of endoneurial origin. J Neurosci Res 1997;49:769-77. (Pubitemid 27430176)
33. Kanda T, Iwasaki T, Yamawaki M, et al. Anti-GM1 antibody facilitates leakage in an in vitro blood-nerve barrier model. Neurology 2000;55:585-7. (Pubitemid 30647264)
34. Engelhardt B. T cell migration into the central nervous system during health and disease: different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol 2010;1:79-93.
35. Takeshita Y, Ransohoff RM. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev 2012;248:228-39.
36. Tarasiuk J, Kulakowska A, Drozdowski W, et al. CSF markers in amyotrophic lateral sclerosis. J Neural Transm 2012;119:747-57.
37. Garbuzova-Davis S, Rodrigues MC, Hernandez-Ontiveros DG, et al. Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res 2011;1398:113-25.
38. Engelhardt B, Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 2008;5:16-22. (Pubitemid 350261811)
39. Miller DH, Soon D, Fernando KT, et al., AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390-401. (Pubitemid 46659091)
40. Wolf C, Menge T, Stenner MP, et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2010;67:881-3.